Skip to content
Cognitive / Nootropic Research compound only, characterised in preclinical studies; not approved for human use in any major jurisdiction, including Australia. Human safety and efficacy data are absent.

Dihexa

Also known as: PNB-0408, N-hexanoic-Tyr-Ile-(6) aminohexanoic acid

Dihexa is a synthetic peptide-derived research compound studied for reported effects on synapse formation and cognition. It is a research compound only and is not approved for human use.

Category
Cognitive / Nootropic
Reported half-life
Not well established
Common forms
Lyophilised powder (research preparations), Research-grade solution
Research status
Research compound only, characterised in preclinical studies; not approved for human use in any major jurisdiction, including Australia. Human safety and efficacy data are absent.
Last updated
21 June 2026

Claimed effects

The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.

  • Reported in animal research to promote synapse formation (synaptogenesis)
  • Studied for possible cognitive effects in preclinical models of impairment
  • Reported to interact with the hepatocyte growth factor (HGF) / c-Met system
  • Early research indicates possible neurotrophic activity

How it is reported to work

Dihexa is a derivative of angiotensin IV and is proposed to act by enhancing hepatocyte growth factor (HGF) signalling through the c-Met receptor, which in animal models is reported to support the formation of new synaptic connections. This proposed mechanism comes from preclinical (animal and laboratory) research and has not been established in humans.

Background

Dihexa is a small synthetic molecule derived from angiotensin IV, developed as a research tool to study synapse formation in the brain. It is an experimental research compound, not a medicine. This page is educational information, not medical advice, and the effects below are reported claims from preclinical work, not established facts.

What the research shows

Most Dihexa data comes from animal and laboratory studies exploring its proposed effect on the HGF/c-Met pathway and synaptogenesis. These results are preliminary and have not been validated in human clinical trials.

Evidence typeStatus
Laboratory / animal studiesPresent
Human clinical trialsAbsent
Australian approvalNone

What people use it for (reported)

Online, some people discuss interest in Dihexa for memory and cognition. These are anecdotal reports with no clinical validation. Reported benefits should not be read as proven, and nothing here is encouragement to use it.

Things to be aware of

Dihexa is an unapproved experimental compound with essentially no human safety data. Because it is reported to act on growth-factor pathways, long-term risks are unknown, and grey-market preparations cannot be verified for purity or identity. If you have cognitive concerns, the appropriate step is to consult a qualified healthcare professional. This article does not recommend obtaining or using Dihexa.

Reported positives & side effects

Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.

Reported positives

  • Reported in animal research to promote synapse formation
  • Reported interest in supporting memory and learning in preclinical models
  • Reported neurotrophic activity via the HGF/c-Met pathway
  • Reported by some users as a subjective cognitive lift

Common side effects

  • Headache reported by some users
  • Irritability or mood changes reported
  • Brain fog or fatigue reported
  • Sleep disturbance reported

Rare / serious side effects

  • Theoretical cancer-growth concern reported due to growth-factor pathway activity
  • Unknown human toxicity given the lack of human safety data
  • Allergic reactions reported
  • Unverified effects from contaminated grey-market product

Reported misuse & overdose risks

What has been reported to happen with overuse, excessive dosing, or long-term misuse of Dihexa. Listed so you can make an informed decision, not to suggest any use is safe.

  • Reported human self-experimentation despite the absence of any human safety data
  • Reported use ignoring the theoretical growth-factor cancer-promotion concern
  • Reported use of unverified grey-market product with no validated dose or purity
  • Reported high or prolonged dosing seeking stronger cognitive effects

Reported results timeline

Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Reported subjective cognitive effects are described over days to weeks, though no human efficacy data confirms any onset.

  1. First effects

    Reported subjective focus changes within days

  2. Noticeable change

    Reported cognitive shifts over one to two weeks

  3. Clear results

    Reported cumulative effects, though unverified in humans

Commonly reported dosing & protocol

Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take Dihexa. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.

Commonly reported dosing for Dihexa
RouteOral (also reported as topical research preparations)
Typical reported doseReported as roughly 8-20 mg per day
FrequencyReported as once daily
Cycle lengthNo human cycle is established; reported anecdotal use spans a few weeks

No human cycle is established; reported anecdotal use involves low daily dosing over a few weeks. Reported information only, not advice.

Best used with / commonly stacked with

Combinations people report using together. Reported, not recommended, stacking can increase risks.

Semax

Reported combined within cognitive-enhancement stacks

Selank

Reported paired to balance stimulation with calm in nootropic stacks

Cerebrolysin

Reported discussed together as neurotrophic-focused compounds

Safety notes

Dihexa is an experimental research compound with no approved human use and very little human safety data. Because it is reported to influence growth-factor pathways, potential long-term effects are unknown and grey-market purity cannot be verified. Anyone with a health concern should consult a qualified healthcare professional rather than self-experiment.

References

  1. PubMed, Dihexa research literature
  2. PubMed, Dihexa angiotensin IV cognition studies